Smoking Cessation and Nicotine De-Addiction Products Market Report 2025

This smoking cessation and nicotine de-addiction products market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The smoking cessation and nicotine de-addiction products market size has grown rapidly in recent years. It will grow from $23.33 billion in 2024 to $25.91 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increasing awareness about the health risks of smoking, government regulations, and anti-smoking policies, availability of a variety of cessation products, support from healthcare professionals, and rising prevalence of smoking-related illnesses.

The smoking cessation and nicotine de-addiction products market size is expected to see rapid growth in the next few years. It will grow to $39.01 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to the growing adoption of digital health solutions, advancements in nicotine replacement therapies, expansion of reimbursement policies, increasing focus on preventive healthcare, and rising public and private investments in smoking cessation programs. Major trends in the forecast period include the development of smart nicotine delivery systems, the use of virtual reality for behavioral therapy, growth in mobile health apps for smoking cessation, advancement in data analytics for personalized cessation plans, and integration of biosensors for real-time monitoring.

The increasing prevalence of smoking-related diseases is anticipated to drive the growth of the smoking cessation and nicotine de-addiction products market. Smoking-related diseases encompass health issues directly linked to tobacco use, such as cancers, respiratory diseases, and cardiovascular conditions. The rise in these diseases is largely due to higher global tobacco consumption and ongoing exposure to harmful tobacco smoke. Smoking cessation and nicotine de-addiction products assist individuals in quitting smoking and reducing nicotine dependency, which helps lower the risk of smoking-related illnesses. For instance, the American Lung Association reported in May 2024 that smoking caused 90% of lung cancer deaths and 80% of chronic obstructive pulmonary disease (COPD) deaths. Chronic lung diseases are present in 73% of current smokers and 50% of former smokers, reflecting an increase in smoking-related diseases. As a result, the growing prevalence of such diseases is expected to boost the market for smoking cessation and nicotine de-addiction products.

Leading companies in the smoking cessation and nicotine de-addiction products market are focusing on developing smart nicotine delivery systems, such as heated tobacco devices, to minimize harmful chemicals and provide a controlled nicotine experience by heating tobacco rather than burning it. In this market, heated tobacco devices serve as a reduced-risk alternative to traditional smoking, helping users gradually transition away from conventional cigarettes. For example, in August 2022, Japan Tobacco Inc., a tobacco manufacturer based in Japan, launched the Ploom X, a sleek and modern heated tobacco device equipped with advanced heating technology that ensures a consistent, satisfying tobacco experience with less smoke and odor. The device features customizable temperature settings, a long-lasting battery with fast charging, and an intuitive LED display with touch controls. Paired with specially designed tobacco sticks to suit various preferences, the Ploom X reflects JT's commitment to offering reduced-risk products (RRPs) while meeting the evolving needs of consumers.

In June 2024, Dr. Reddy's (RDY), a pharmaceutical company based in India, acquired Haleon for an undisclosed amount. This acquisition is part of Dr. Reddy's strategy to strengthen its position in the over-the-counter (OTC) drug market by adding Haleon's nicotine addiction drug portfolio. Haleon, a UK-based company, specializes in nicotine de-addiction products.

Major companies operating in the smoking cessation and nicotine de-addiction products market are Pfizer Inc., Philip Morris International Inc., Johnson & Johnson Inc., Merck & Co. Inc., AstraZeneca PLC, Imperial Brands plc, GlaxoSmithKline plc, British American Tobacco plc, Dr Reddy’s Laboratories Ltd, Cipla Ltd, Cambrex Corp, Rusan Pharma Ltd, Perrigo Company plc, Fertin Pharma, 22nd Century Group Inc., Alchem International Pvt Ltd, McNeil AB, Chrono Therapeutics Inc., Enorama Pharma AB, Smoke Away LLC.

North America was the largest region in the smoking cessation and nicotine de-addiction products market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the smoking cessation and nicotine de-addiction products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smoking cessation and nicotine de-addiction products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Smoking cessation and nicotine de-addiction products are designed to assist individuals in quitting smoking and overcoming nicotine dependence. These include nicotine replacement therapies, prescription medications, and behavioral support programs. Such products aim to help individuals stop smoking by alleviating cravings, managing withdrawal symptoms, and facilitating behavioral changes.

Key types of smoking cessation and nicotine de-addiction products include nicotine replacement therapy (NRT) items, drug therapies, nicotine sublingual tablets, nicotine inhalers, and e-cigarettes. NRT products provide a controlled dose of nicotine to ease withdrawal symptoms and come in various forms such as gum, inhalers, and tablets. These products are available through drug stores, hospital pharmacies, online pharmacies, and retail pharmacies.

The smoking cessation and nicotine de-addiction products market research report is one of a series of new reports that provides smoking cessation and nicotine de-addiction products market statistics, including smoking cessation and nicotine de-addiction products industry global market size, regional shares, competitors with a smoking cessation and nicotine de-addiction products market share, detailed smoking cessation and nicotine de-addiction products market segments, market trends and opportunities, and any further data you may need to thrive in the smoking cessation and nicotine de-addiction products industry. This smoking cessation and nicotine de-addiction products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The smoking cessation and nicotine de-addiction products market consists of sales of nicotine nasal spray, nicotine mouth spray, herbal smoking cessation products, nicotine lozenge tablets, and acupuncture kits for smoking cessation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.